enVVeno Medical (NVNO) AI Stock Analysis

• Market Cap: $6.79M
• Dividend Yield: N/A
• Average Volume (3M): 589.93K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.91
• Revenue Growth: N/A
• EPS Growth: 18.94%
• Country: US
• Employees: 37
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.23
• Shares Outstanding: 20,216,175
• 10 Day Avg. Volume: 395,892
• 30 Day Avg. Volume: 589,933
• PEG Ratio: 0.07
• Price to Book (P/B): 1.23
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.07
• Enterprise Value/Market Cap: 6.91
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -95.03
• Enterprise Value/Ebitda: -2.19
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: $0.32 ▼(-3.33% Downside)

The score is driven primarily by weak financial performance (no revenue, sizable losses, and continued cash burn), compounded by a bearish technical setup (price below all key moving averages and negative MACD). Negative corporate events (FDA setback and Nasdaq bid-price compliance risk) add further downside risk, while valuation support is limited due to negative earnings and no indicated dividend.

Positive Factors

Strong Equity Position

A strong equity position with minimal leverage indicates financial stability and reduced financial risk, providing a solid foundation for future growth initiatives.

Innovative Product Pipeline

The development of a non-surgical venous valve demonstrates innovation and potential for market expansion, addressing safety concerns and enhancing treatment options.

Strategic Partnerships

Strategic partnerships enhance product validation and distribution capabilities, supporting revenue growth and market penetration in the healthcare sector.

Negative Factors

Profitability Issues

Severe profitability issues with highly negative margins indicate operational challenges, requiring strategic shifts to achieve sustainable financial performance.

FDA Approval Setback

The FDA's non-approval of VenoValve poses a significant setback, impacting product commercialization timelines and necessitating additional development efforts.

Negative Cash Flow

Insufficient cash flow generation from operations limits financial flexibility and necessitates improvements to sustain long-term viability and investment capacity.

enVVeno Medical Business Overview & Revenue Model

Company Description

enVVeno Medical Corporation, a medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of severe deep venous chronic venous insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.

How the Company Makes Money

enVVeno Medical makes money by developing, manufacturing, and selling medical devices designed to treat venous diseases. The company's primary revenue stream comes from the sales of its proprietary products aimed at improving venous valve function, particularly for patients with chronic venous insufficiency. Key factors contributing to its earnings include product sales to healthcare providers, partnerships with medical institutions for clinical trials and product distribution, and potentially licensing or royalty agreements related to its patented technologies. The company's ability to generate revenue is closely tied to the successful commercialization of its products and the establishment of strategic partnerships within the healthcare industry.

enVVeno Medical Financial Statement Overview

Summary

enVVeno Medical faces significant financial challenges, marked by substantial losses and negative cash flows. The income statement shows severe profitability issues with highly negative margins. The balance sheet, however, indicates strong financial stability due to low leverage and high equity. Cash flow analysis reveals insufficient cash flow generation from operations, necessitating strategic initiatives for improvement.

Income Statement

enVVeno Medical's income statement reveals a challenging financial position. The company has only recently generated revenue in the TTM period, with a gross profit margin of 17.37%. However, net income remains significantly negative, resulting in a net profit margin of -2626.72%. The EBIT and EBITDA margins also indicate substantial losses, at -2866.26% and -2819.95% respectively. These figures highlight ongoing operational challenges and a need for strategic shifts to improve profitability.

Balance Sheet

The balance sheet of enVVeno Medical shows a strong equity position with a low debt-to-equity ratio of 0.03, indicating minimal leverage and financial risk. The equity ratio stands at 94.40%, underlining substantial equity financing. However, the company's return on equity is negative at -55.68%, reflecting the impact of net losses. Despite the robust equity standing, profitability remains a significant concern.

Cash Flow

The cash flow analysis for enVVeno Medical reflects negative operating and free cash flows, with a free cash flow growth rate of -2.73% from the previous year. The operating cash flow to net income ratio is 0.81 for the TTM period, indicating that cash flows are not sufficient to cover net losses. While financing activities have contributed positively, the company must improve cash flow generation from operations to sustain long-term viability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-494.00K	-528.00K	-546.00K	-525.00K	-452.91K	-383.97K
EBITDA	-21.47M	-21.29M	-22.97M	-24.14M	-16.07M	-8.75M
Net Income	-21.96M	-21.82M	-23.52M	-24.67M	-16.53M	-9.14M
Balance Sheet
Total Assets	32.35M	44.95M	48.63M	41.66M	57.70M	10.54M
Cash, Cash Equivalents and Short-Term Investments	30.95M	43.15M	46.41M	39.04M	54.73M	9.33M
Total Debt	791.00K	1.06M	1.40M	1.72M	2.01M	880.65K
Total Liabilities	2.90M	2.79M	2.44M	2.93M	3.29M	3.44M
Stockholders Equity	29.45M	42.16M	46.20M	38.73M	54.40M	7.10M
Cash Flow
Free Cash Flow	-17.24M	-16.88M	-18.89M	-15.73M	-12.21M	-7.86M
Operating Cash Flow	-17.23M	-16.84M	-18.86M	-15.62M	-11.85M	-7.68M
Investing Cash Flow	618.00K	1.33M	-7.87M	-34.55M	-367.89K	-180.29K
Financing Cash Flow	241.00K	13.64M	25.79M	0.00	57.61M	15.07M

enVVeno Medical Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.33
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NVNO, the sentiment is Negative. The current price of 0.33 is below the 20-day moving average (MA) of 0.34, below the 50-day MA of 0.41, and below the 200-day MA of 2.20, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 41.81 is Neutral, neither overbought nor oversold. The STOCH value of 40.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NVNO.

enVVeno Medical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TNON	49 Neutral	$10.59M	-0.35	-197.26%	―	-2.47%	91.23%
PAVM	45 Neutral	$8.64M	-0.48	20.03%	―	-99.28%	-46.16%
CTSO	44 Neutral	$44.04M	-3.84	-96.15%	―	-8.97%	47.29%
NVNO	43 Neutral	$6.79M	-0.30	-57.19%	―	―	18.94%
COCH	42 Neutral	$20.60M	-0.51	―	―	-25.18%	-9.71%
SINT	40 Underperform	$14.75M	-0.55	-204.04%	―	-60.89%	94.49%

enVVeno Medical Corporate Events

enVVeno Medical Holds Annual Stockholders Meeting

On December 11, 2025, enVVeno Medical Corporation held its Annual Meeting of Stockholders, where 54.70% of the voting power was represented. During the meeting, Matthew M. Jenusaitis and Robert A. Berman were elected as Class II directors, the compensation of named executive officers was approved on a non-binding basis, and CBIZ CPAs P.C. was ratified as the public accounting firm for 2025. However, the 2025 Equity Incentive Plan was not adopted, and the 2016 Omnibus Incentive Plan remains in effect. Additionally, the Board was granted authority to effectuate a reverse stock split at a ratio between one-for-five and one-for-thirty-five at their discretion.

enVVeno Medical Amends Quorum Requirement for Meetings

On November 17, 2025, enVVeno Medical Corporation’s Board of Directors approved an amendment to the company’s bylaws, specifically modifying the quorum requirement for stockholder meetings. The new amendment stipulates that a quorum is constituted by the presence, in person or by proxy, of holders of thirty-three and one-third percent of the voting power of outstanding shares, effective immediately upon approval.

enVVeno Medical Faces FDA Setback on VenoValve

On November 13, 2025, enVVeno Medical Corporation announced that it received an unfavorable decision from the FDA regarding its appeal for the Premarket Approval of VenoValve®, a surgical replacement venous valve for severe deep chronic venous insufficiency. Despite the setback, the company gained valuable insights for its next-generation transcatheter-based valve, enVVe, which is ready for human testing. The company plans to focus resources on enVVe, aiming to align with the FDA on achievable endpoints. enVVeno reported having $31.5 million in cash and investments, sufficient to fund operations into 2027.

enVVeno Medical Launches $50M Equity Offering Program

On October 30, 2025, enVVeno Medical Corporation entered into an At-the-Market Offering Agreement with Ladenburg Thalmann & Co. Inc. to establish an equity program allowing the sale of up to $50 million in common stock. This agreement enables enVVeno to sell shares at market prices through ordinary brokers’ transactions on the NASDAQ Capital Market, with the agent receiving a 3% commission on sales. The company retains the flexibility to suspend or terminate the agreement at any time, impacting its financial strategy and market positioning.

enVVeno Medical Faces Nasdaq Delisting Notice

On October 7, 2025, enVVeno Medical Corporation was notified by Nasdaq that its common stock had fallen below the $1.00 per share minimum bid price requirement for 30 consecutive business days, putting it out of compliance with Nasdaq’s listing rules. The company has until April 6, 2026, to regain compliance by ensuring its stock closes at or above $1.00 for at least 10 consecutive trading days. Failure to comply could lead to delisting, though the company may qualify for an additional compliance period and has the right to appeal any delisting decision.